%0 Journal Article %T Clues to improve the cost-effectiveness of radiotherapy for brain metastases from non-small cell lung cancer: cost reduction, patient selection, and better understanding of neurocognitive deterioration %A Saito, Hirotake %A Nakano, Toshimichi %A Aoyama, Hidefumi %J Annals of Palliative Medicine %D 2018 %B 2018 %9 %! Clues to improve the cost-effectiveness of radiotherapy for brain metastases from non-small cell lung cancer: cost reduction, patient selection, and better understanding of neurocognitive deterioration %K %X In September 2018, Girard et al . published the article ‘ Extra cost of brain metastases (BM) in patients with non-squamous non-small cell lung cancer (NSCLC): A French national hospital database analysis ’ (1). They extracted the data of 2,500 metastatic NSCLC patients from the national medical information database and divided the patients into two groups: those with metastases other than brain (n=1,529), and those with BMs (n=971). The study’s analyses revealed that the presence of BM at diagnosis contributed to the excessive medical cost of €553 per patient-month, and Girard et al . stated that radiotherapy (RT) and palliative care are the principal components of the increased cost. %U https://apm.amegroups.org/article/view/22872 %V 8 %N 2 %P 199-202 %@ 2224-5839